Journal
NATURE MEDICINE
Volume 21, Issue 6, Pages 560-562Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nm.3854
Keywords
-
Funding
- National Cancer Institute of the National Institutes of Health [R01CA135257, R01CA114465, P01CA154303]
- AstraZeneca
- Conquer Cancer Foundation of ASCO
- Stading-Younger Cancer Research Foundation
- Department of Medical Oncology at Dana-Farber Cancer Institute
Ask authors/readers for more resources
Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291. We first performed next-generation sequencing of cfDNA from seven subjects and detected an acquired EGFR C797S mutation in one; expression of this mutant EGFR construct in a cell line rendered it resistant to AZD9291. We then performed droplet digital PCR on serial cfDNA specimens collected from 15 AZD9291-treated subjects. All were positive for the T790M mutation before treatment, but upon developing AZD9291 resistance three molecular subtypes emerged: six cases acquired the C797S mutation, five cases maintained the T790M mutation but did not acquire the C797S mutation and four cases lost the T790M mutation despite the presence of the underlying EGFR activating mutation. Our findings provide insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291 and highlight the need for therapies that are able to overcome resistance mediated by the EGFR C797S mutation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available